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Abstract
Coronary fibromuscular dysplasia is uncommon, and even rarer its unstable and recurrent course. We present the unique case
of a 52-year-old woman who underwent in total 12 coronary angiographies and three percutaneous coronary intervention
within 24 months because of repetitive acute coronary syndromes due to refractory spasm, dissection, restenosis all leading
to end-stage heart failure, and heart transplantation. The patient died 12 days after the heart transplantation complicated by
intraoperative acute thrombotic occlusion of left anterior descending artery of the graft despite normal pretransplant coronary
angiography. Autopsy of the recipient heart confirmed coronary fibromuscular dysplasia with massive intimal hyperplasia and
restenosis.
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Introduction
Fibromuscular dysplasia (FMD) is a nonatherosclerotic, nonin-
flammatory artery disease, mainly affecting middle-aged
women (female to male ratio 9:1). FMD may affect any artery,
but most commonly (about 65% of cases), it is found in the ca-
rotid or renal artery.1–3 Coronary FMD is infrequent (about
0.6–5%), and its manifestations are nonspecific including dis-
section, spasm, tubular narrowing, or tortuosity.4–6 No
evidence-based management on diagnosis and treatment cur-
rently exists, so a case-by-case approach discussed within a
multidisciplinary heart team is desirable. Conservative treat-
ment is pursued in most acute coronary FMD events. In unsta-
ble patients with ongoing myocardial ischaemia or severe
recurrent symptoms and who may require an interventional
approach, therapeutic options remain unsatisfactory.
Case report
A 52-year-old, non-smoking woman with hypertension,
dyslipidaemia, and recurrent migraine presented to the
emergency department with acute chest pain associated with
electrocardiogram showing ST-segment depression in leads
V3–V6 (Figure 1A), evolving early into widespread ST-
segment changes pathognomonic for critical lesion of the left
main (LM) coronary artery (Figure 1B), and associated with el-
evated blood troponin I and creatine kinase (60.98 μg/L and
2247 U/L, respectively). Transmural myocardial infarction
was confirmed at coronary angiography with 90% stenosis
of the LM and diffuse spasm of the left coronary artery.
Intracoronary nitrates resolved the spasm; however, the ste-
nosis of the ostial and mid-LM persisted (Figure 1C). Given
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emergent conditions, primary percutaneous coronary inter-
vention (PCI) and 10 mm biolimus-eluting stenting of the
LM culprit lesion were performed.7,8 Intravascular ultrasound
(IVUS) confirmed correct stent position and TIMI-3 flow was
observed. The patient received secondary prevention therapy
for ischaemic coronary artery disease (CAD) at discharge, in-
cluding aspirin, ticagrelor, metoprolol, perindopril, and
rosuvastatin.
One month later, the patient experienced ischaemic stroke
due to dissection of the internal carotid artery (Figure 2A). In
view of these two acute vascular events, according to
guidelines,1–3 we evaluated other arterial beds and found
multifocal bilateral stenosis of renal arteries (Figure 2B).
Four months later (Table 1), the patient started to present
recurrent acute non-ST-segment elevation myocardial infarc-
tions (NSTEMIs). She underwent serial coronary angiogra-
phies including optical coherence tomography (OCT), which
showed mild restenosis but no dissection in the previously
stented LM, while angiography revealed severe coronary ar-
tery spasm (CAS) of the ostial-proximal left anterior descend-
ing (LAD) and left circumflex artery (LCX), which almost
completely disappeared at both sides after intracoronary
Figure 1 (A) First resting electrocardiogram on admission with 2 mm ST-segment depression in leads V3 to V6. (B) Dynamic changes of the electro-
cardiogram with widespread horizontal ST-segment depression most prominent in leads I, II, and V4–V6, and ST-segment elevation in aVR, pathogno-
monic for critical lesion of the LM. (C) Coronary angiography after intracoronary injection of nitrates, showing persistence of the ostial and mid-LM
stenosis (arrow).
Figure 2 Peripheral vessels of the patient presented as maximum intensity projection (MIP) images of magnetic resonance angiographies (MRA). (A)
Left carotid bifurcation and spontaneous dissection of mid and distal segment of extracranial internal carotid artery (ICA) (arrows). CCA, common ca-
rotid artery; ECA, external carotid artery. (B) Renal arteries with a bilateral ‘string of beads’ sign (arrows), which is virtually pathognomonic for multi-
focal, medial type fibromuscular dysplasia.
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nitrates. Conservative treatment including non-
dihydropyridine calcium-channel blocker, nitrates, nicorandil,
and ranolazine at maximal tolerated doses was gradually
implemented.4
Nevertheless, three months later, the patient suffered a
witnessed out-of-hospital cardiac arrest (OHCA). Immediately
after successful resuscitation, coronary angiography was per-
formed, showing 90–99% stenosis of the bifurcation of LAD
and LCX (Medina classification 0,1,1) (Figure 3A). OCT ruled
out dissection or significant atherosclerosis but showed wide-
spread intima thickening. Intracoronary nitrates rapidly re-
duced the angiographic obstruction (final TIMI-3 flow),
suggesting severe spasm as the cause of OHCA on top of tu-
bular restenosis (Figure 3B). However, conservative strategy
for spasm early proved ineffective, as the patient presented
with ongoing diffuse transmural myocardial ischaemia and
haemodynamic instability. The case was discussed within
our multidisciplinary heart team, and an interventional ap-
proach by PCI and double off-label everolimus-eluting biore-
sorbable scaffold (BRS) were performed. An implantable
cardioverter defibrillator (ICD) was also implanted for second-
ary prevention.9
Next months were characterized by recurrent NSTEMIs,
which were assumed a result of drug-resistant CAS. Following
several reports of cervical sympathectomy being potentially
beneficial in such cases, this thoracoscopic procedure was of-
fered to the patient, but she refused.10
Six months after the OHCA, in-stent restenosis due to ex-
cessive neointimal hyperplasia of the previously stented bi-
furcation occurred (Figures 4A and 4B). Moreover, OCT
Table 1 Two-year course of coronary complications of FMD
Time (months) Event
0 LM occlusion
4–6 Recurrent CAS
6 OHCA
6–12 Recurrent CAS
12 In-stent restenosis of LAD and LCX
12 Suspected dissection of LM
20 Thrombotic complete occlusion of LAD
24 HTX and acute occlusion of LAD of the graft
CAS, coronary artery spasm; FMD, fibromuscular dysplasia; HTX,
orthotopic heart transplantation; LAD, left anterior descending ar-
tery; LCX, left circumflex artery; LM, left main coronary artery;
OHCA, out-of-hospital cardiac arrest.
Figure 3 (A) Emergency coronary angiography performed just after the out-of-hospital cardiac arrest, showing severe 90–99% stenosis of the bifur-
cation of left anterior descending and left circumflex artery (Medina classification 0,1,1) due to coronary spasm. (B) Angiographic result of rapid reduc-
tion of obstruction after intracoronary injection of nitrates (final TIMI-3 flow).
Figure 4 Follow-up: 6 months after the out-of-hospital cardiac arrest: over 90% angiographic stenosis of left circumflex artery (A) and the optical co-
herence tomography image of excessive neointimal hyperplasia (B) causing a significant restenosis of the previously stented bifurcation of left anterior
descending and left circumflex artery. (C) optical coherence tomography image of a dissection of left main beneath the first implanted stent.
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revealed LM dissection beneath the first implanted stent as-
sociated with strut rupture (Figure 4C). This dissection might
be retrospectively suspected to be a cause of the primary
event, although its location, beneath a ruptured stent, makes
this hypothesis difficult to verify.
Finally, 20 months after the initial event, the patient ex-
perienced anterior ST-segment elevation myocardial infarc-
tion due to acute complete occlusion of proximal LAD,
which may have been fostered by the previously implanted
BRS. This event led to a severe reduction of left ventricular
ejection fraction of less than 20%, and rapidly deteriorating
end-stage heart failure. The decision was to put the patient
on a super-urgent waiting list for orthotopic heart transplan-
tation (HTX). A 50-year-old donor heart was checked by an-
giography before explant with no evidence of CAD.
Nevertheless, immediately after implant of the donor heart,
surgeons observed no flow in the LAD of the graft (Figure
5A). Regardless of emergency double venous bypass graft,
a cardiogenic shock occurred, complicated later by multi-
organ failure and disseminated intravascular coagulation.
Histopathology of specimen extracted by angiography from
the graft LAD showed a fresh white artery thrombus as
the cause of the vessel occlusion (Figure 5B). The patient
died after 12 days on extracorporeal membrane
oxygenation.
Post-mortem autopsy samples of coronary arteries from
the recipient heart showed a typical pattern of coronary
intimal-type FMD: excessive intimal hyperplasia with ‘star-
shaped’ lumen and concentric adventitial fibrosis (Figure
5C), without any alterations typical of atherosclerosis or vas-
culitis.1,2,11 Moreover, massive occlusive in-stent restenosis
was visualized, which is notably associated with both FMD
and BRS (Figure 5D).
Discussion
The case describes a highly unstable, treatment-resistant
(conservative and interventional) combination of coronary
complications resulting in refractory CAS, dissection, stent-
related complications progressively leading to end-stage
heart failure. This recurrent presentation is probably due to
a combination of various factors: local characteristics of a le-
sion, systemic factors, iatrogenic impact of PCI, and BRS, pos-
sibly aggravated by predisposing local factors as restenosis
highlighted in the histopathological image with severe intimal
hyperplasia (Figure 5C).
The patient underwent PCI with stent for the first severe
LM obstruction. According to the European guidelines for
Figure 5 (A) Intraoperative coronary angiography of the graft with a significant occlusion of the left anterior descending. (B) Atherectomy specimen of
the left anterior descending of the graft with an occlusive white thrombus within the lumen. (C) Autopsy sample of the coronary artery from the pa-
tient’s explanted heart with massive in-stent restenosis due to excessive intimal hyperplasia, probably secondary to both fibromuscular dysplasia and
bioabsorbable stenting (white arrow). Moreover, concentric adventitial fibrosis can be noticed (black arrow). (D) Typical pattern described in coronary,
intimal-type fibromuscular dysplasia: excessive intimal hyperplasia with a ‘star-shaped’ lumen (white arrow) and concentric adventitial fibrosis (black
arrow). Haematoxylin and eosin staining.
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management of unprotected LM disease available at that mo-
ment,7 coronary artery bypass grafting was recommended re-
gardless of anatomic complexity for revascularization for
stable CAD. However, PCI could be considered for selected
LM lesions depending on lesion location, vessel involvement,
and SYNTAX score, especially for ostial or mid-lesion and low
SYNTAX score, as in our case. In emergent condition and
acute myocardial infarction, LM PCI appeared to have re-
markably high (89%) in-hospital survival.8 Use of IVUS is rec-
ommended in decision-making process. In our case, no
initial dissection was detectable by IVUS. The remote possibil-
ity that the patient could have presented dissection as an ini-
tial event cannot completely be excluded because OCT was
not performed given the acute presentation.
The patient presented the OHCA, which was caused by se-
vere CAS. Stent placement is a therapeutic alternative in pa-
tients with spasm refractory to maximal aggressive medical
therapy.12 Patients resuscitated from cardiac arrest and pre-
senting with CAS have a poorer prognosis and show a high
prevalence of ICD therapy for ventricular arrhythmias.9
Therefore, our patient also underwent an ICD implantation
for secondary prevention of sudden cardiac death.
Retrospectively, we have to admit that the use of BRS was
definitely a wrong decision and led to catastrophic acceler-
ated clinical course in the patient with FMD. Concerns about
restoration of vessel functionality and thrombogenicity were
not available at the time these stents were delivered.13 Next
recurrent NSTEMIs could be associated with both drug-
resistant CAS, which is frequently reported with coronary
FMD,4,5 and CAS triggered by BRS.14 We may hypothesize
that the final acute complete occlusion of LAD was due to late
acute thrombotic occlusion probably due to the presence of
previously implanted BRS. Retrospectively, another alterna-
tive hypothesis of this acute occlusion should be taken into
account: progressive massive intimal hyperplasia due to
FMD and aggravated by BRS (Figure 5C), over time, led to
sub-occlusion of the vessel with recurrent nitrates-resistant
CAS. The final complete catastrophic occlusion of LAD may
have also been caused by severe CAS over the sub-occluded
vessel.
The patient underwent HTX, which was complicated by in-
traoperative acute akinesia of the new heart due to throm-
botic occlusion of the graft LAD. Early coronary
complications of HTX are very rare and mainly associated with
procedural manipulation or directly related to donor heart,
especially with CAD,15,16 as transmitted atherosclerosis re-
sults in a two-fold to three-fold increased risk for early graft
failure.17 Most eurotransplat regions recommend to screen
every donor over 40 years old by angiography or when it is
requested by surgeon (also in our case), when some risk fac-
tors are suspected. The question if donor heart angiography
increases endothelium trauma is difficult to answer. We could
not find any literature specific for heart donors. However, a
similar question was posed for kidney donors.18 The authors
conclude that the administration of contrast medium had
no influence on renal function at 3 or 6 months after trans-
plantation, so in conclusion, fears that donor kidneys might
be harmed by contrast medium appeared to be unfounded.
The young donor heart in our case presented no evidence
of CAD at pretransplant angiography. In vivo thrombus ex-
traction during angiography before patient death revealed a
white artery thrombus of the LAD, indicating a recent coro-
nary thrombotic event (Figure 5B). Peri-procedural related in-
flammation and thrombogenicity increase a risk of myocardial
ischaemia.15 Although painful attention was paid to avoid
mechanical damage during the transplantation procedures,
the probable cause of the unexpected fatal finding could be
related to inadvertent embolism due to manipulation during
the complex HTX procedure or, less probably, secondary to
hyperacute vascular rejection (although preoperatively direct
lymphocyte crossmatch test was negative),19,20 or to a puta-
tive presence of systemic vascular disease.21–23
Histopathological examination of recipient heart confirmed
intimal-type FMD (Figure 5D). According to the European and
US consensus,1,2 intimal-type FMD is associated with focal an-
giographic pattern mainly localized at ostial or proximal part
of a vessel, in contrast to medial type, which is rather associ-
ated with multifocal pattern located at mid or distal vessel.
However, two types can coexist in one subject, as shown in
our case by a presence of multifocal bilateral renal artery ste-
nosis and intimal histopathological type of coronary arteries.
In general, coronary FMD has a good prognosis (low mortality
0.8% during a median follow-up period of 23.9 months), and
conservative medical treatment for acute events, as dissec-
tion or spasm, is recommended, as most of lesions heal spon-
taneously. Aggressive measures as PCI, coronary artery
bypass grafting, or even HTX, as only means of establishing
coronary flow, can be considered only in life-threading or
with ongoing ischaemia cases.6
Starting from the first event and during the whole 2-year
course, the patient was closely monitored by our heart team
and differential diagnosis was performed as follows. Review
of laboratory testing showed normal inflammation parame-
ters (especially no C-reactive protein or eosinophils), normal
coagulation factors, catecholamine level, and autoimmune
panel. Medical history and clinical findings reasonably exclude
in a well compliant patient other possible triggers such as
over-the-counter antimigraine medications, as well as alcohol
and abuse of recreational drugs (marijuana and amphet-
amine).24 The patient’s history reveals involvement of periph-
eral vessels (carotid dissection and bilateral multifocal renal
artery stenosis), and family history was positive for the pa-
tient’s brother having dissection of the vertebral artery at
the age of 27. All these findings, together with histopatholog-
ical findings, were consistent with the diagnosis of multivessel
FMD and reasonably ruled out alternative diagnoses such as
aortic dissection, pseudoxantoma elasticum, vasculities,
Marfan syndrome, Shprintzen-Goldberg syndrome, Ehlers–
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Danlos syndrome, segmental arterial mediolysis, or Loeys-
Dietz syndrome.25–27
In conclusion, coronary FMD has generally a favourable
prognosis, and conservative treatment is preferred. This case
of unstable coronary FMD rapidly leading to end-stage heart
failure and treatment-resistant fatal evolution illustrates elu-
siveness of diagnosis and dilemma, challenges, and potential
harm of invasive treatment of coronary FMD. The optimal
management of patient with FMD and end-stage heart failure
unfortunately is unknown given a rarity of the condition, and
there is a growing need for more studies in these patients
based on international large population registries. The acute
fatal thrombotic coronary complication during HTX remains
so far unexplained.
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